
Melanoma is a highly immunogenic cancer, and circannual rhythms influence the activity of the immune system.We retrospectively collected information on all cases with metastatic melanoma (ocular melanoma excluded) that initiated treatment with BRAF‐inhibitor‐based therapy (BRAFi) or anti‐PD‐1 monotherapy (PD‐1). Cases where divided in two groups based on treatment initiation in the summer half‐year (April to September) or winter half‐ collected a total of 1054 (BRAF‐i) and 1205 (PD‐1) patient cases. We did not observe differences in outcomes across patients who were treated in summer versus winter in the BRAFi cohort. However, in patients with BRAF wild‐type disease of the PD‐1 cohort, treatment initiation in summer was associated with an improved OS. This result remained robust to multivariable proportional hazards of immunotherapy in summer is associated with prolonged survival in patients with BRAF wild‐type melanoma living in Denmark.
Like
Save
Share